Hello, Ramjet, I have an opinion on your question

Hello, Ramjet, I have an opinion on your question -

"Do we have to have new data from the studies and trials outstanding or is there enough for a deal on an indication?"

- but fyi, EVERY opinion I've had on the possibility of a deal has been wrong since March of 2020, i.e., when I bought my first shares @ a SP of $1.03

In short, based on Leronlimab's success with AIDS patients, I think every major biopharma is aware of the molecule's efficacy and safety. And since they're staffed with their own "Ohms," I also believe they are fully aware of our potential across a wide swath of diseases.

But since we sit at 11 cents/share, and since we were at about 30 cents a share just before I bought in back in March 2020, I have to believe there is a deliberate effort to suppress our SP. There is no other molecule like ours, nothing so safe and with so much potential (at least none that I've heard of), so the ONLY thing that makes 11 cents/share possible is deliberate suppression.

Large biopharmas want us to crash and burn, and "they" had enough influence with the FDA to keep a molecule with an absolutely stellar safety profile on a safety hold for 2 years.

So, "is there enough for a deal on an indication?" Absolutely. And when dangerous Alzheimers drugs are approved that do nothing, when Remdesivir was approved that either killed or made patients demonstrably worse?

"They" value profits or people. The suppression of our SP is a crime against the sick and diseased, and I hope, really hope and pray that the new FDA is not like the old FDA.

If we get a believer in LL at the top of the FDA or CDC or NIH or HHS?
Who knows, that might be all it takes.